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INTRODUCTION
Clinical proteomics focusing on the identification and validation of biomarkers and the discovery of proteins as therapeutic targets is an emerging and highly important area of proteomics. Biomarkers are measurable indicators of a specific biological state, particularly one relevant to the risk of contraction, the presence or the stage of disease, and thus expected to be useful for the prediction, detection, and diagnosis of disease as well as to follow the efficacy, toxicology, and side effects of drug treatment, and to provide new functional insights into biological processes.
At present, proteomics methods based on mass spectrometry (MS) have emerged as the preferred strategy for discovery of diagnostic, prognostic, and therapeutic protein biomarkers. Most biomarker discovery studies use unbiased, "identified-based" approaches that rely on high performance mass spectrometers and extensive sample processing. Semi-quantitative comparisons of protein relative abundance between disease and control patient sample are used to identify proteins that are differentially expressed and, thus, to populate lists of potential biomarkers. De novo proteomics discovery experiments often result in tens to hundreds of candidate biomarkers that must be subsequently verified in serum. However, despite the large numbers of putative biomarkers, only a small number of them are passed through the development and validation process into clinical practice and their rate of introduction is declining.
Targeted proteomics employing multiple reaction monitoring (MRM) is emerging as a technology that complements the discovery capabilities of shotgun strategies as well as an alternative powerful novel mass spectrometry-based approach to measure a series of candidate biomarkers (1) (2) (3) (4) (5) (6) (7) . Therefore, MRM is expected to provide a powerful high throughput platform for biomarker validation, though clinical validation of novel biomarkers has been relying traditionally on immunoassays (8, 9) . MRM exploits the unique capabilities of triple quadrupoles (QQQ) MS for quantitative analysis. In MRM, the first and the third quadrupoles act as filters to specifically select predefined m/z values corresponding to the peptide precursor ion and specific fragment ion of the peptide, whereas the second quadrupole serves as collision cell. Several such transitions (precursor/fragment ion pairs) are monitored over time, yielding a set of chromatographic traces with retention time and signal intensity for a specific transition as coordinates. These measurements have been multiplexed to provide 30 or more specific assays in one run. Such methods are slowly gaining acceptance in the clinical laboratory for the routine measurement of endogenous metabolites (10) (e.g. in screening newborns for a panel of inborn errors of metabolism) and some drugs (11) (e.g. immunosuppressants), and the component analysis of sugars (12) .
One of the profound challenges in clinical proteomics is the need to handle highly complex biological mixtures. This complexity presents unique analytical challenges that are further magnified with the use of clinical serum/plasma samples to search for novel biomarkers of human disease. The serum proteome is composed of tens of thousands of unique proteins, of which concentrations may exceed 10 orders of magnitude. Protein glycosylation, one of the most common post-translational modifications, generates tremendous diversity, complexity and heterogeneity of gene products. It changes the biological and physical properties of proteins, which include functions as signals or ligands to control their distribution, antigenicity, metabolic fate, stability, and solubility. Protein glycosylation, in particular by N-linked glycans, is prevalent in proteins destined for extracellular environments. These include proteins on the extracellular side of the plasma membrane, secreted proteins and proteins contained in body fluids (such as blood serum, cerebrospinal fluid, urine, breast milk, saliva, lung lavage fluid or pancreatic juice). Considering that such body fluids are most easily accessible for diagnostic and therapeutic purposes, it is not surprising that many clinical biomarkers and therapeutic targets are glycoproteins. These include, for example, CA125 in ovarian cancer, human epidermal growth factor receptor 2 (Her2/neu) in breast cancer, and PSA in prostate cancer. In addition, changes in the extent of glycosylation and the structure of N-glycans or O-glycans attached to proteins on the cell surface and in body fluids have been shown to correlate with cancer and other disease states, highlighting the clinical importance of this modification as an indicator or effector of pathologic mechanisms (13) (14) (15) (16) . Thus, we thought that clinical proteomic platforms should have capability to provide protein glycosylation information as well as sufficient analytical depth to reliably detect and quantify specific proteins with sufficient accuracy and throughput.
To improve the detection limits to the required sensitivities, one needs to dramatically reduce the complexity of the sera samples.
For the focused glycoproteomics, several techniques using lectins or antibodies enabling the large scale identification of glycoproteins have recently been developed (17) (18) (19) hours. For removal of peptides, asialoglycopeptides and other components, the resin was washed thoroughly with water (1 ml), 1 M NaCl (1 ml), 30% MeOH (1 ml), 0.1% acetic acid (1 ml), and water (1 ml). The resin was then treated with ice-cold 1 M HCl (500 µl) under cooling in an ice bath, and filtered quickly. To the solution was then quadrupoles to maximize specificity and the scan rate on Q3 was 4000 amu/sec. The acquired MS/MS spectra of PA-labeled sialyl glycopeptides from mouse serum were searched from identified de-glycosylated peptides after the treatment with PNGase F, which can be identified from the ion sets of specific peptide fragment containing single GlcNAc residue and the corresponding non-glycosylated (naked) peptide fragment.
The fact that retention time of glycopeptide is closely related to that of de-glycosylated peptides (core peptides) should greatly assist above searching analysis. Search parameters included carbamidomethylation of cysteins and oxidized methionines;
trypsin digestion with partially site-cleavages (semi-trypsin); variable modifications including pyro-glutamic acid and aspartic acid to identify a number of peptides (38, 39) .
A mass tolerance for the precursor ions and the fragments ions were 1. 
RESULTS

Principle of reverse glycoblotting technique designated for sialyl glycopeptides-focused MRM assays.
The basic strategy for multiplexed quantitative glycoproteomics of mouse serum samples (50 µl) based on the reverse glycoblotting method and LC-MRM assays was outlined in Figure 1 . The objective of this approach is the generation of reproducible glycopeptide patterns representing the serum glycoproteome, leading to the quantitative detection of specific glycopeptides that discriminate between related groups of glycoproteomes and the subsequent identification of these discriminatory glycopeptides.
We herein established a novel method for the enrichment analysis of serum glycopeptides bearing sialic acids, in which non-reducing sugar residues are labeled selectively by reductive amination of the aldehyde group generated at C7 position of sialic acid with 2-aminopyridine (Scheme 1). This improved process greatly facilitated further LC-MS and MS/MS characterization involving MRM-based measurements of mouse serum glycopeptides because pyridyl aminated (PA-labeled) glycopeptides allowed for general fluorescence detection. In our previous report (27),
we employed an aminooxy-functionalized polyacrylamide for the enrichment of glycopeptides having at least one terminal sialic acid. This protocol is based on the formation of stable oxime bond between aldehyde groups generated by selective oxidation at glycerol moiety of sialic acid residues and aminooxy groups of polymer supports. Glycopeptides captured are therefore recovered as their asialo-forms due to this stable oxime linkage, since the treatment with 3% trifluoroacetic acid (TFA) at 100ºC for 1 h, a common condition to cleave oxime bonds, was proved to digest predominantly the glycoside linkage between sialic acid and galactose residues. Thus, 
Identification of mouse serum sialyl glycopeptides by LC-MS and MS/MS.
Mouse serum PA-labeled sialyl glycopeptides enriched by reverse glycoblotting protocol were subjected to LC-MS analysis according to the systematic strategy shown in Figure 1 . It is clear that the digestion of PA-labeled N-glycans from glycopeptides proceeded smoothly by treating with PNGase F, since LC profiles monitored by fluorescence detector changed dramatically to converge at early retention times after de-N-glycosylation ( Figure 2A) . Interestingly, the retention times due to original glycopeptides and the corresponding naked peptides were found to be in close proximity on the reversed-phased chromatography while peak numbers were reduced by PNGase digestion, indicating the existence of significant heterogeneity in glycan structures at individual N-glycosylation sites ( Figure 2B ). For example, MS/MS analysis revealed that a glycopeptide from alpha-1-acid glycoprotein 1 and its de-N-glycosylated peptide were eluted at 45.9 and 49.1 min, respectively ( Figure 2C and 2D). De-N-glycosylated peptides were subjected to the pattern matching analysis based on the MS/MS analysis and the mass of discriminatory peptides was determined using in-house MASCOT server and Protein Pilot TM sotware. Eventually, we identified 270 unique sialylated glycopeptides mapping to 95 unique sialylated glycoproteins by reverse glycoblotting method as shown in Table 1 and Figure 3 . It should be noted that two peptide search algorithm significantly influences the fragment scoring calculation of the number of matching between the row data and the theoretical fragment ions to afford differences in the identified glycopeptides/glycoproteins (44) (45) (46) . Table 2 ) from alpha-2-macroglobulin (NYLNETQQLTEAIK).
Design of MRM assays for PA-labeled sialyl glycopeptides.
In MRM experiments, two mass analyzers (Q1 and Q3) are used as static mass filters to monitor a particular fragment ion of a selected precursor ion ( Figure 4A ). Unlike conventional shotgun proteomic studies, MRM measurements are strictly targeting a predetermined set of peptides and depend strongly on specific MRM transitions (specific pair of m/z values associated with the precursor and fragment ions selected) for each targeted peptides. Since the intensities of individual fragments derived from one precursor ion differ substantially, it is essential to select transitions specific for the most intense fragments to obtain a high-sensitivity assay. For this purpose, 67 MS/MS spectra of glycopeptides from 26 mouse serum glycoproteins were actually obtained, and information on peptide sequence, glycoform, observed parent mass, and retention time on reversed phase chromatography were also summarized in Table 2 . The optimization of collision energy (CE) was carried out for 38 glycopeptides to achieve high sensitivity and efficiency in the detection of specific fragment ions (Supplemental Figure 3 ).
Regardless the peptide sequences, the MS/MS cleavage occurs preferentially between the two GlcNAc residues of the core chitobiose, resulting in peptide fragment ion retaining one GlcNAc residue on the asparagine residue with high intensity ( Figure   4B ). Therefore, we selected a fragment ion containing the innermost GlcNAc residue as key transitions. Basically, the choice of the transitions is observed parents mass as Q1 filter, observed fragment ions as Q3 filter, and the collision energy (CE) is selected from optimal CE guided to several measurements with different CE on the basis of observed MS/MS analysis with rolling collision energy program ( Figure 4C and 4D ).
As anticipated, the obtained MRM setting named as MRM channel for PA-labeled yolk glycopeptide as an internal standard showed high sensitivity and reproducibility ( Figure   4D and 4E, Supplemental Figure 4 ). It was also demonstrated that relationship between fragment ion counts and the amount of PA-labeled glycopeptide tested exhibited a good linearity at a range from 1 to 6 pmole. It is not surprising that condition for the preparation of tryptic peptides from serum samples often influences mass-based quantitative proteomics because common biological sample consists of various factors affecting profiles of tryptic digests such as endogenous proteases and protease inhibitors (21) . Thus, we examined the effect of this step during sample preparation on the reproducibility and concluded that repetitive tryptic digests provide highly stable and reliable MRM assay of PA-labeled sialyl glycopeptides enriched by reverse glycoblotting method (Supplemental Figure 6 ). In addition, it was demonstrated that the use of an internal standard (PA-labeled sialyl glycopeptides derived from egg yolk) allows for calibration of the raw data to determine the relative concentrations of targeted glycopeptides in MRM assays (Supplemental Figure 7) . However, it must be noted that these relative concentrations estimated by comparing with an internal standard spiked are not actual concentration in mouse serum due to the different ionization potentials of individual glycopeptides (6) . 29. Nilsson J., Rüetschi U., Halim A., Hesse C., Carlsohn E., Brinkmalm G., Larson G., Enrichment of glycopeptides for glycan structure and attachment site identification. Nat. Figure 9 .
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